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Abstract  
BACKGROUND: The poor prognosis and rising incidence of esophageal 
adenocarcinoma highlight the need for improved detection methods. The potential for 
circulating miRNAs as biomarkers in other cancers has been shown, but circulating 
miRNAs have not been well characterized in esophageal adenocarcinoma. We 
investigated whether circulating exosomal miRNAs have potential to discriminate 
individuals with esophageal adenocarcinoma from healthy controls and non-
dysplastic Barrett’s esophagus.  
METHODS: 754 miRNAs were profiled in serum circulating exosomes from a 
cohort of 19 healthy controls, 10 individuals with Barrett’s esophagus and 18 
individuals with locally advanced esophageal adenocarcinoma. MiRNA expression 
was assessed using all possible permutations of miRNA ratios per individual.  
RESULTS: 408 miRNA ratios were differentially expressed in individuals with 
cancer compared to controls and Barrett’s esophagus (Mann Whitney U test, P<0.05). 
179/408 ratios discriminated esophageal adenocarcinoma from healthy controls and 
Barrett’s esophagus (linear regression, P<0.05; Area under ROC>0.7, P<0.05). A 
multi-biomarker panel (RNU6-1/ miR-16-5p, miR-25-3p/ miR-320a, let-7e-5p/ miR-
15b-5p, miR-30a-5p/ miR-324-5p, miR-17-5p/ miR-194-5p) demonstrated enhanced 
specificity and sensitivity (Area under ROC=0.99, 95%CI 0.96-1.0) over single 
miRNA ratios to distinguish esophageal adenocarcinoma from controls and Barrett’s 
esophagus.   
CONCLUSIONS: This study highlights the potential for serum exosomal miRNAs 
as biomarkers for the detection of esophageal adenocarcinoma.  
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INTRODUCTION 
Esophageal adenocarcinoma is one of the deadliest cancers, with an overall mortality 
rate of 85-90%. Its incidence has increased 6-fold over the past 3-4 decades [1, 2]. As 
outcomes are better when this cancer is treated early, endoscopy surveillance of 
individuals with the precursor Barrett’s esophagus is undertaken to identify 
individuals who might benefit from early intervention. However, the annual rate of 
progression to cancer is reported to range from 0.12 to 0.4% [3], so the cost 
effectiveness of Barrett’s esophagus surveillance has been questioned [4]. If less 
invasive detection tools such as a reliable blood test can be developed, then it might 
be possible to reduce dependence on endoscopy surveillance in high risk individuals, 
or more cost effective surveillance strategies might be developed. 
 
MicroRNAs (miRNAs) are small non-coding 21-23 nucleotide RNA molecules, 
which regulate the production of proteins from mRNA [5, 6]. They are found in the 
cell free fraction of blood, including serum, and can be reliably measured from frozen 
stored samples [7]. Circulating miRNAs levels have recently been used to identify 
some cancers [8, 9]. miRNAs circulating in serum are present in a variety of forms, 
including within small extracellular microvesicles known as exosomes. Exosomes are 
shed by tumor cells, and can enter the circulation. Significantly, circulating miRNAs 
in exosomes are more stable than other forms, as they are protected from endogenous 
RNase degradation [10, 11], and have significant potential as disease specific 
biomarkers. 
 
Unique circulating exosomal miRNAs signatures have been recently identified in 
colon cancer [12]. Robust studies evaluating circulating exosomal miRNAs signatures 
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in esophageal cancer are yet to be reported, with the only recent studies limited to 
either esophageal squamous cell carcinoma cell lines, or a very small clinical cohort 
(eight individuals with esophageal adenocarcinoma vs. four controls) in which a 
broad discovery approach was not applied [13-15]. Hence, to evaluate the potential 
for circulating miRNAs in exosomes to be used as biomarkers for esophageal 
adenocarcinoma, we applied a broader discovery approach to investigate levels of 
circulating exosomal miRNAs in serum from individuals with esophageal 
adenocarcinoma, compared to non-dysplastic Barrett’s esophagus and age-matched 
controls. This approach was used to determine the potential for circulating miRNAs in 
exosomes to be used to identify individuals with esophageal adenocarcinoma. 
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MATERIALS AND METHODS 
Patient recruitment 
In our institution, individuals undergoing upper gastrointestinal endoscopy at Flinders 
Medical Centre in Adelaide, South Australia, were recruited to a research study that 
included collection and storage of blood samples for biomarker research. Other 
individuals presenting to the Royal Adelaide Hospital, Adelaide, South Australia, for 
investigation and treatment of esophageal cancer were also recruited to a parallel 
study that included collection of blood samples for biomarker research. Blood 
samples from 47 individuals who met the following criteria were selected for the 
current study (Figure 1):  
i) Healthy controls (n=19). These individuals had blood collection prior to an 
endoscopy that was unrelated to investigation of cancer, Barrett’s esophagus 
or gastroesophageal reflux. At endoscopy no abnormality was identified, and 
the presence of Barrett’s esophagus, upper gastrointestinal cancer or 
gastroesophageal reflux was excluded. 
ii) Individuals diagnosed with non-dysplastic Barrett’s esophagus (n=10). 
These individuals had blood collection prior to endoscopy, Barrett’s 
esophagus >2cm in length (median 4cm ± 1.5) was visualized at the 
endoscopy, and Barrett’s esophagus was confirmed by mucosal biopsy that 
showed histopathological evidence of intestinal metaplasia but no dysplasia. 
iii) Individuals diagnosed with locally advanced esophageal adenocarcinoma 
(n=18). These individuals also had blood collection prior to endoscopy at 
Flinders Medical Centre or imaging investigation at the Royal Adelaide 
Hospital. Esophageal adenocarcinoma was confirmed by histopathology, and 
staging investigations (CT scan, PET scan and endoscopic Ultrasound) 
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confirmed clinical T staging of T3 or higher in all instances. All bloods 
collected from these individuals were taken before any treatment (either 
surgery and/or chemoradiotherapy). 14 of these individuals were staged after 
surgical resection (T3, n=13; T4, n=1), and 4 had metastatic disease and did 
not undergo surgery for their advanced cancer (all T3 or T4).  
As esophageal adenocarcinoma is associated with a strong male gender bias of up to 
8:1 [16], all individuals contributing blood samples for this study were male. In 
addition the Barrett’s esophagus and control groups were age matched to the cancer 
group with median age 70 ± 13, 65 ± 14 and 66 ± 10 respectively (p=0.25, ANOVA). 
 
The recruitment and blood collection was approved by the Southern Adelaide Clinical 
Human Research Ethics Committee and the Royal Adelaide Hospital Research Ethics 
Committee, and all individuals gave written informed consent for blood and data 
collection and use in this study. The research work was conducted in accordance with 
the Declaration of Helsinki’s (2008) Statement of ethical principles for medical 
research involving human subjects. 
 
Blood processing, serum exosome isolation and Exosome miRNA extraction  
Blood was collected in a serum clot activator tube and then processed by 
centrifugation. Centrifugation was performed at 400g for 15min, and 1ml aliquots of 
serum were stored in eppendorf tubes at -80°C for later use. Serum aliquots from 
individuals selected for this study were retrieved from storage, quick thawed, and 
centrifuged again at 16,000g at 4°C for 30min to remove large microparticles. To 
isolate exosomes, 250μl of supernatant was processed with ExoQuickTM (System 
Biosciences, EXOQ20A-1) according to the manufacturer’s protocol. All serum 
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samples were incubated with ExoQuickTM for 16h. The acquired exosome pellet was 
resuspended in 50μl phosphate buffered saline (PBS). The presence of particles 
consistent in size with exosomes (60-150nm) was confirmed using a Nanosight LM10 
Nanoparticle Analysis System and Nanoparticle Tracking Analysis Software 
(Nanosight Ltd).  
 
Extraction of miRNA from exosomes was then performed using the commercial 
miRNeasy Serum/Plasma kit (Qiagen, #217184) according to the manufacturer’s 
protocol. All RNA elution steps were carried out at 10,000g for 15s. Final RNA 
elution was performed with 24μl of RNase-free ultra pure water per sample.  
 
TaqMan OpenArray miRNA profiling 
The high throughput TaqMan® OpenArray® Human microRNA panel (Life 
technologies, #4461104) was used for miRNA profiling. This panel comprised 754 
human miRNAs probes that are based on miRNA sequences derived from Sanger 
miRBase v14. For each sample, 3μl of RNA was reverse transcribed using pre-
defined RT-primers (MegaplexTM Primer Human Pool A and Pool B) and the 
TaqMan® microRNA Reverse Transcription Kit (Life technologies, #4366596). Pre-
amplifications were carried out with MegaplexTM PreAmp Pools and TaqMan 
PreAmp Master Mix on 7.5μl cDNA/ sample for each pool. The pre-amplified 
products (4μl per sample) were diluted at the recommended 1:40 dilution with 156μl 
of RNase-free ultra pure water before loading onto the 384-well TaqMan OpenArray 
loading plate. PCR runs were performed using the Biotrove OpenArray NT cycler at 
Flinders Genomics Facility, Flinders University.  
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Expression and statistical analyses 
The cycle threshold (Ct) value per assay was assessed using the RealTime PCR 
Statminer® software analysis program (v4.5, Integromics). Integrity of the Cts 
obtained with these settings was checked on a subset of samples by manually 
assessing the amplification via the raw fluorescent signals. Only miRNAs with 
detectable Cts in all samples were considered for the expression analysis. The relative 
expression of each detectable miRNA was calculated as 2(40-Ct). Relative expression 
values for each miRNA were used to derive per patient values for every possible 
permutation of miRNA ratios. Open ArrayTM data were deposited in the Gene 
Expression Omnibus (www.ncbi.nlm.nih.gov/geo; GEO accession number 
GSE63108). 
 
Significant miRNA expression differences were determined using Mann-Whitney U 
test (P<0.05) (R version 3.0.2). Prediction performance of each miRNA ratio 
candidate was assessed using linear regression (R version 3.0.2) and Receiver 
Operating Characteristic (ROC) curve analysis (SPSS v22, Inc). Unsupervised 
clustering was used to generate a heatmap of the miRNA signature using Genepattern 
version 3.9 (Broad Institute). Stepwise multiple linear regression was used to generate 
a potential multiple biomarkers panel (SPSS v22, Inc). The sequential statistical 
approach to identify potential biomarker candidates and the multiple biomarkers panel 
was checked by leave-one-out cross validation (R version 3.0.2). 
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RESULTS 
 
Expression profiling of circulating miRNAs to identify a miRNA ratio signature 
in esophageal adenocarcinoma 
Circulating serum exosomal miRNAs were profiled using the high throughput 
Taqman OpenArray qPCR platform. 100 miRNAs had detectable Cts in all 47 
individuals. To identify reliable and reproducible miRNA biomarkers, expression 
analysis was confined to these miRNAs. MiRNA expression data values were then 
derived for all possible permutations of miRNA ratios within each individual. This 
ratio method was identical to that utilized by Boeri et al [17] in an analysis of data 
from individuals with lung cancer. Altogether 9900 miRNA ratios were obtained. 
Selection of the miRNA ratios with potential diagnostic value was performed using 
sequential testing as described in Figure 1. 408/9900 miRNA ratios were commonly 
differentially expressed in esophageal adenocarcinoma compared to healthy controls 
and in esophageal adenocarcinoma compared to non-dysplastic Barrett’s esophagus 
(Mann-Whitney U test, P<0.05). This first subset of 408 miRNA ratios was then 
assessed by both linear regression and ROC curve analysis to determine their 
prediction performance for discriminating patients with esophageal adenocarcinoma 
from healthy controls and those with non-dysplastic Barrett’s esophagus. 179/408 
miRNA ratios were identified to have potential diagnostic value by linear regression 
analysis (P<0.05) and ROC (AUROC>0.7, P<0.05). This list of 179 miRNA ratios 
consisted of 82 highly expressed miRNA ratios, and 97 lowly expressed miRNA 
ratios, in individuals with esophageal adenocarcinoma compared to both healthy 
controls and Barrett’s esophagus (Figure 2). 
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Potential benefit of combining multiple miRNA ratios into a biomarker panel 
To investigate the potential of combining multiple miRNA ratios and compare its 
performance to a single miRNA ratio, stepwise multiple linear regression analysis 
was performed on the 179 miRNA ratios. Five miRNA ratios derived from 10 unique 
markers, RNU6-1/ miR-16-5p, miR-25-3p/ miR-320a, let-7e-5p/ miR-15b-5p, miR-
30a-5p/ miR-324-5p and miR-17-5p/ miR-194-5p, were determined to be a potential 
multiple biomarkers panel that could discriminate individuals with esophageal 
adenocarcinoma from controls and Barrett’s esophagus (Table 1). These 5 miRNA 
ratios were identified to be significant independent biomarkers (standardized 
regression coefficients, P<0.05). Subsequent inclusion of each of the ratios 
contributed significantly to the model, as demonstrated by significant F change of 
increase in adjusted R2, with a final adjusted R2 of 0.70 (Table 1). The distribution 
and normality plots of the standardized residuals for the multiple biomarkers model 
did not suggest any abnormality or outliers (Supplementary Figure 1). The validity of 
the full sequential statistical methods used in this study, from the initial biomarkers 
selection (Mann-whitney, linear regression and ROC analyses) to the modeling of 
biomarkers combination with stepwise multiple linear regression, were confirmed by 
leave-one-out cross validation (Supplementary Table 1). 
 
3/5 ratios were significantly elevated in esophageal adenocarcinoma whereas 2/5 
ratios were decreased in esophageal adenocarcinoma compared to controls and 
Barrett’s esophagus (Table 2). RNU6-1/ miR-16-5p was the most highly expressed 
miRNA ratio in cancers, with 3.7 fold and 3.8 fold difference compared to controls 
and Barrett’s esophagus respectively. While miR-30a-5p/ miR-324-5p was the most 
decreased miRNA ratio in cancers compared to controls (3-fold difference) and 
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Barrett’s esophagus (1.6 fold difference). The expression of each of the 5 miRNA 
ratios were comparable between controls and Barrett’s esophagus (Supplementary 
Figure 2).  
 
Prediction performance of the 5-miRNA ratios combination compared to single 
miRNA ratios 
The prediction accuracy of the 5 miRNA ratios as independent biomarkers and as a 
combined biomarkers panel were evaluated by ROC curve analysis. The single best 
performing biomarker was the top highly expressed miRNA ratio in esophageal 
adenocarcinoma, RNU6-1/ miR-16-5p, with an AUROC of 0.89 (95% CI 0.79-1.00) 
(Figure 3). The combination of all the 5 miRNA ratios significantly enhanced the 
prediction accuracy to an overall AUROC of 0.99 (95% CI 0.96-1.00) (Figure 3). 
 
To further investigate how each of the 5 miRNA ratios would add value to the 
biomarker panel, the accuracy of predicting cancer in a patient was assessed per 
addition of each miRNA ratio (Table 3). RNU6-1/ miR-16-5p as a single biomarker 
predicted 14/18 cancer patients (78% accuracy). Stepwise inclusion of the remaining 
4 miRNA ratios to RNU6-1/miR-16-5p in the panel demonstrated improved 
prediction accuracy, up to 94% prediction accuracy when all 5 miRNA ratios were 
included. The AUROC increased at each inclusion step, further supporting that each 
ratio added to the panel provided some prediction value.  The improvement of 
prediction accuracy by adding more than 1 miRNA ratio in the biomarker panel was 
further supported by the leave-on-out cross validation (Supplementary Figure 3). 
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DISCUSSION 
To our knowledge, this is the first study to comprehensively profile and compare 
circulating exosomal serum miRNAs in esophageal adenocarcinoma, non-dysplastic 
Barrett’s esophagus and healthy controls. We identified a miRNA signature of 179 
miRNA ratios and a multiple biomarkers panel of 5 miRNA ratios, which have 
potential diagnostic value for esophageal adenocarcinoma. The study was designed as 
the initial step towards developing clinically applicable diagnostic biomarkers. The 
results of our study support further investigation in expanded cohorts, and within an 
expanded range of disease cohorts. 
 
In our current study, the 5-miRNA ratios biomarker panel consisted of several 
miRNAs known to be associated in cancers as either oncogenes or tumor suppressors. 
Notably, 5/9 of the miRNAs in the multiple biomarkers panel have been reported 
previously to be differentially expressed between Barrett’s esophagus and esophageal 
adenocarcinoma in human tissues [18-20]. In a Taqman miRNA profiling study on 
human tissues, Wu et al found that miR-25-3p is progressively overexpressed from 
normal esophageal epithelium to non-dysplastic Barrett’s esophagus, dysplastic 
Barrett’s esophagus, and to esophageal adenocarcinoma [19]. A small tissue 
biomarker pilot study also indicated that miR-15b-5p expression alone discriminated 
non-dysplastic Barrett’s esophagus from dysplastic Barrett’s esophagus and 
esophageal adenocarcinoma (87% sensitivity and 80% specificity) [18]. Importantly, 
comparison between our current serum based study and a previous study undertaken 
in our laboratory which evaluated tissue based miRNAs associated with development 
of esophageal adenocarcinoma identified an overlap of 4 miRNAs, miR-194-5p, miR-
30a-5p, miR-15b-5p and miR-17-5p [20]. miR-194-5p and miR-30a-5p have been 
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shown to be associated with epithelial-mesenchymal transition, which is one of the 
hallmarks of more aggressive cancers [21, 22]. Recent studies have demonstrated an 
important role for miR-15b-5p (and miR-16-5p that lies in the same genomic cluster), 
in regulating apoptosis, cell cycle and DNA repair pathways [23], and highlighted 
miR-15b-5p as a potential target for anti-cancer therapies [24]. Finally, miR-17-5p 
belongs to one of the most well-studied oncogenic miRNA clusters, miR-17/92, 
commonly found to be overexpressed in solid tumors including gastric and colorectal 
cancers [25]. The miR-17/92 cluster family of miRNAs has been shown to target 
universal cancer genes such as PTEN and E2F which are critical for regulating cell 
growth and cell death [25]. Altogether, these findings suggest that changes in the 
expression of tissue miRNAs with biological roles in the malignant degeneration of 
esophageal tissue may be reflected in the serum exosomes of the individuals. 
 
The ratio method used in our study was the same as that utilized by Boeri et al to 
develop diagnostic and prognostic miRNA signatures for lung cancer [17]. Boeri et al 
recently validated their miRNA signature in a large cohort of individuals with lung 
cancer [26], highlighting the potential for application in other cancers. We adopted 
this method to overcome the limitations associated with global normalization 
approaches. Reliable normalization is absolutely vital for an accurate assessment of 
circulating miRNA data. However, this remains one of the main challenges for studies 
on expression analysis of circulating miRNAs due to a lack of established universal 
housekeeping genes and standardized approach for serum samples [27-29]. 
Furthermore, while global normalization may be deemed as the currently more 
acceptable method for large miRNA datasets, it is not realistic to implement its usage 
in the clinical setting. Currently, the common housekeeping genes include small 
  
16 
16 
nuclear/nucleolar RNAs such as RNU44, RNU48 and RNU6-1, also more commonly 
known as U6. The spliceosome complex, which catalyzes pre-mRNA splicing, and in 
which U6 is a key functional component, is frequently deregulated in a wide variety 
of cancers [30]. Consistent with this and with our findings, it has been shown that 
serum RNU6-1 levels are differentially expressed in serum from individuals with 
breast cancer compared to healthy controls [31]. In addition, a recent miRNA 
profiling study performed on the serum exosomes in individuals with glioblastoma 
identified RNU6-1 as a potential diagnostic cancer biomarker [32]. Thus, at least in 
the context of serum miRNA profiling studies in cancers, we propose that RNU6-1 is 
not suitable for use as a normalization control gene, and alternative methods of 
analysis are required. 
 
A strength of our current study, at least from a clinical translation perspective, is the 
use of serum rather than tissue biomarkers. A significant issue with biomarker studies 
that utilize esophageal adenocarcinoma cancer tissues is heterogeneity within 
individual cancers. This can impact on the reproducibility of study outcomes, and 
hence translation to clinical practice. Heterogeneity generates sampling issues, as 
different patterns of expression can be identified in different samples from different 
parts of the same tumor from the same individual. This is a particular problem when 
studies use small endoscopic biopsies, as these are inevitably collected from different 
parts of the tumor. Blood and serum derived biomarkers, however, offer an 
opportunity to overcome this sampling problem, and serum derived diagnostic 
biomarkers miRNAs for esophageal adenocarcinoma, if appropriately validated, 
might be more robust and therefore more readily translated into a clinical useful 
blood-based test. 
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There are limitations to our current study, and more work is required to investigate the 
specificity and sensitivity of serum exosomal microRNAs for esophageal 
adenocarcinoma. In this study, all individuals with cancer had locally advanced 
disease, and we did not evaluate serum from individuals with early stage cancer (T1) 
or high grade dysplasia in Barrett’s esophagus. If this approach and the current 
biomarker panel can be used to distinguish individuals with very early stage cancer 
from those with Barrett’s esophagus then the serum biomarker panel could be used for 
surveillance of individuals with Barrett’s esophagus, and new paradigms for 
surveillance could be developed which reduce the need for endoscopy. However, 
more work is required using serum from cohorts with early esophageal 
adenocarcinoma and high grade dysplasia in Barrett’s esophagus to address this 
question. In addition, our study has only examined esophageal adenocarcinoma, and 
not other cancer types, so the biomarker panel must also be tested against other 
cancers, including gastrointestinal cancers and other cancer types, to determine its 
specificity to esophageal adenocarcinoma. However, the outcomes of the current 
study do demonstrate significant potential for serum exosomal miRNAs to be 
developed for cancer diagnosis, and more work to address this is certainly justified.  
 
The potential advantage of combining multiple biomarkers vs. the use of single 
biomarkers alone was demonstrated in this study. However, due to the small cohort 
size, we were unable to fully investigate other factors required in developing a multi-
biomarkers panel. For instance, we were unable to use our current cohort to determine 
the appropriate number of biomarkers that can be included in a single panel. This 
would require a larger cohort with the extended disease groups mentioned above.  
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In conclusion, our study has demonstrated that circulating exosomal miRNAs have 
potential to act as diagnostic biomarkers for esophageal adenocarcinoma, and 
combining miRNAs might improve the sensitivity and specificity of this approach. 
However, the limited size of the cohort studied, and the need to test the markers in 
other clinical cohorts means that more work is required before considering broader 
clinical application.  We anticipate that our study’s findings will encourage future 
studies to investigate circulating miRNAs for clinical utility in esophageal 
adenocarcinoma and other cancers.  
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Table 1: Stepwise multiple regression model of the multiple biomarkers panel of 5 
miRNA ratios that discriminated individuals with esophageal adenocarcinoma from 
healthy controls and Barrett’s esophagus. The order of display of each miRNA ratio 
refers to the order of their stepwise inclusion in the regression model.  
 
Model 
Standardized 
Coefficients 
R 
R-
square 
Adjusted  
R-square 
F change 
P value Beta t P 
value 
RNU6-1/ miR-16-
5p 
0.324 3.36 0.002 0.65 0.42 0.41 <0.001 
miR-25-3p/ miR-
320a 
0.452 5.37 <0.001 0.74 0.55 0.53 0.001 
Let-7e-5p/miR-
15b-5p 
0.313 3.40 0.002 0.81 0.66 0.64 0.001 
miR-30a-5p/miR-
324-5p 
-0.213 -2.59 0.01 0.84 0.70 0.67 0.03 
miR-17-5p/miR-
194-5p 
-0.217 -2.34 0.02 0.86* 0.73* 0.70* 0.02* 
*Predictors: constant, RNU6-1/ miR-16-5p, miR-25-3p/miR-320a, let-7e-5p/ miR-15b-5p, 
miR-30a-5p/ miR324-5p, miR-17-5p/ miR-194-5p (5-ratio panel) 
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Table 2: Fold difference for the 5 miRNA ratios for esophageal adenocarcinoma vs. 
Controls (Healthy controls and individuals with Barrett’s esophagus).  
 
miRNA ratios 
Cancer vs Controls Cancer vs Barrett’s 
Fold 
difference 
P value 
Fold 
difference 
P value 
RNU6-1/ miR-16-5p 3.7 <0.001 3.8 <0.001 
miR-25-3p/ miR-320a 1.4 0.03 2.3 0.002 
Let-7e-5p/miR-15b-5p 1.6 0.002 1.8 <0.001 
miR-30a-5p/miR-324-5p 0.3 <0.001 0.6 0.03 
miR-17-5p/miR-194-5p 0.5 0.003 0.6 0.003 
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Table 3: Prediction accuracy for Cancer following stepwise inclusion of each of the 5 
miRNA ratios derived from the regression model. 
 
 
Model Prediction of cancer in 
top 18 possibilities 
AUROC (95% CI) 
U6/miR-16 14 0.89 (0.79-1) 
U6/miR-16 
miR-25/miR-320 
16 0.93 (0.83-1) 
U6/miR-16 
miR-25/miR-320 
let-7e/ miR15b 
15 0.97 (0.94-1) 
U6/miR-16 
miR-25/miR-320 
let-7e/ miR15b 
miR-30a-5p/ miR-324 
17 0.98 (0.96-1) 
U6/miR-16 
miR-25/miR-320 
let-7e/ miR15b 
miR-30a-5p/ miR-324 
miR-17/miR-194 
17 0.99 (0.96-1) 
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Supplementary Table 1. Predicted probability that each left-out patient in the leave-
one-out cross validation has cancer. Each probability was determined using a regression 
model of a 5 miRNA-ratio panel derived with the sequential testing method utilised in 
this study. Out of the 18 actual cancer patients in the cohort, The leave-one-out cross 
validation correctly identified 13 cancer patients from the 18 individuals (highlighted 
in grey) with the highest predicted probabilities of being a cancer based on the 
regression model. 
 
Actual disease state Predicted probability to be Cancer  
Cancer 1.00 
Cancer 1.00 
Cancer 1.00 
Cancer 1.00 
Cancer 0.98 
Control 0.97 
Cancer 0.95 
Barrett's 0.95 
Cancer 0.90 
Cancer 0.83 
Control 0.80 
Cancer 0.80 
Control 0.80 
Cancer 0.68 
Cancer 0.62 
Control 0.54 
Cancer 0.49 
Cancer 0.45 
Control 0.44 
Cancer 0.42 
Control 0.38 
Control 0.20 
Barrett's 0.18 
Control 0.15 
Control 0.15 
Cancer 0.14 
Control 0.13 
Control 0.12 
Barrett's 0.11 
Barrett's 0.09 
Control 0.08 
Control 0.08 
Barrett's 0.08 
Control 0.07 
Barrett's 0.07 
Control 0.05 
Barrett's 0.04 
Cancer 0.04 
Barrett's 0.03 
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Cancer 0.03 
Control 0.03 
Control 0.02 
Barrett's 0.02 
Control 0.02 
Control 0.02 
Barrett's 0.01 
Cancer 0.00 
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FIGURE LEGENDS 
 
Figure 1: Study design and approach to biomarker selection. 
 
Figure 2: The expressions of 179 miRNA ratios in serum circulating exosomes were 
significantly different between healthy controls or patients with non-dysplastic 
Barrett’s esophagus compared to patients with esophageal adenocarcinoma (Mann-
Whitney U-test and linear regression, P<0.05). All ratios achieved an AUROC >0.7 in 
ROC curves for the discrimination of esophageal adenocarcinoma from controls and 
Barrett’s esophagus.  
 
Figure 3: ROC curves for the combined 5 miRNA ratios biomarker panel compared to 
individual miRNA ratios as single biomarkers, demonstrating better sensitivity and 
specificity for identifying individuals with esophageal adenocarcinoma vs. controls.  
 
Supplementary Figure 1: Distribution (A) and normality plots (B) of the standardized 
residuals of the combined 5-miRNA ratios biomarker panel. 
 
Supplementary Figure 2: Distribution of the 5 miRNA ratios in healthy controls, 
Barrett’s esophagus and esophageal adenocarcinoma. 
 
Supplementary Figure 3:  LOOCV prediction errors for increasing numbers of ratios 
in the final regression model. Error rate is the number of cancers that were 
misclassified, as a percentage.    
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Patient Selection
1. Healthy controls (n=19) without Barrett's 
esophagus and upper GI cancers       * Males only, age-matched
2. Barrett's esophagus (n=10) without dysplasia
3. Locally advanced esophageal adenocarcinoma 
(n=18) with stage T3, T4
miRNA extraction from serum exosomes
Taqman OpenArray miRNA profiling
Analysis of miRNA expression
1. Inclusion of miRNAs detected in all samples only
2. Relative expression of miRNAs within an
individual was defined by deriving all possible 
miRNA ratios per sample (n=9900 ratios)
Sequetial testing to select miRNA ratios 
biomarkers candidates  
 
Selection test 1- Mann-Whitney U test 
408 ratios differentially expressed in cancers 
(P<0.05) compared to controls/ Barrett's esophagus 
 
Selection test 2- Linear regression and ROC 
179/408 ratios discriminated cancers from controls/ 
Barrett's esophagus in both linear regression 
(P<0.05) and ROC (AUROC 0.7, P<0.05) 
 
Modeling of multiple biomarkers panel 
Stepwise multiple linear regression on 179 
ratios identified a 5-miRNA ratios panel that 
discriminated cancers from controls/ 
Barrett's esophagus  
Methods used to identify biomarkers candidates and 
modeling of potential multiple biomarkers panel 
assessed by leave-one-out cross validation  
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